Enviaments recents

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Pfeiler, Georg; Hlauschek, Dominik; Mayer, Erica; Lambertini, Matteo; Agostinetto, Elisa; de Azambuja, Evandro; Bellet Ezquerra, Meritxell (Data de publicació: 2025-03-17)

Breast cancer; Palbociclib; Proton pump inhibitors

Precision Oncology: A Global Perspective on Implementation and Policy Development

Horgan, Denis; Tanner, Marcel; AGGARWAL, CHARU; Thomas, David; Grover, Surbhi; Basel-Salmon, Lina; Dienstmann, Rodrigo (Data de publicació: 2025-03-17)

Precision Oncology; Policy development

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Rastogi, P.; Martin, M.; Tolaney, Sara M; Shao, Zhi Min; Cortés Castan, Javier; Fasching, Peter A.; Harbeck, Nadia (Data de publicació: 2022-06-13)

Abemaciclib; Adjuvant; Early breast cancer

Barriers to publishing early phase clinical trials: the oncologists’ perspective

Lucassen, Merel; Bergmann, Pedro; Husson, Olga; Basu, Bristi; Banerji, Udai; MELERO BERMEJO, IGNACIO; GARRALDA, Elena (Data de publicació: 2025-07-02)

Ethics; Medical oncology; Publication

Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein

Castillo, Francisco; Beaulieu, Marie-Eve; Soucek, Laura (Data de publicació: 2021-09-01)

Myc; descobriment de fàrmacs; Interaccions proteïna-ADN

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents

Casartelli, Chiara; Tommasi, Chiara; Lazzarin, Alessandro; Corianò, Matilde; Tornali, C.; Serra, Olga; Gutiérrez-Enríquez, Sara; Llop-Guevara, Alba; Serra, Violeta (Data de publicació: 2024-07-10)

Gene function; DNA

DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas

Statz-Geary, Kurt; Elliott, Andrew; Bialick, Steven; Oberley, Matthew; Serrano, Cesar; von Mehren, Margaret (Data de publicació: 2025-09-05)

DNA damage response; Precision medicine; Sarcoma

Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients

Estrada, Natalia; Palomo Diaz, Laura; García, Olga; Vélez, Patricia; Ferrer-Marin, Francisca; Zamora, Lurdes (Data de publicació: 2022-11-23)

Chronic myeloid leukemia; Imatinib; Single-nucleotide polymorphisms

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

Jiménez, Natalia; Garcia de Herreros, Marta; Reig Torras, Oscar; Marín-Aguilera, Mercedes; Aversa, Caterina; Ferrer-Mileo, Laura; CROS COSTA, SARA; Carles, Joan; Suárez, Cristina (Data de publicació: 2024-03-27)

Androgen deprivation therapy; Biomarkers; Prostate cancer

Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology

Stanley, Kate; Jatsenko, Tatjana; Tuveri, Stefania; Sudhakaran, Dhanya; Lannoo, Lore; Van Calsteren, Kristel; Toledo, Rodrigo (Data de publicació: 2024-03-20)

Cell-free DNA fragmentation; Cancer

Mass Spectrometry-Based Proteomics Workflows in Cancer Research: The Relevance of Choosing the Right Steps

Carrillo Rodriguez, Paula; Selheim, Frode; Hernandez-Valladares, Maria del Carmen (Data de publicació: 2023-03-01)

Mass spectrometry; Proteomics; Workflows

An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry

Perret, Camille; Hackshaw, Allan; Nabholz, Christoph; Geissler, Jan; Le Tourneau, Christophe; Blay, Jean-Yves; Dienstmann, Rodrigo (Data de publicació: 2022-10-25)

Oncología de precisión; Datos clinicogenómicos

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Cho, Byoung Chul; Gutiérrez, Vanesa Lores; alip, adlinda; Lu, Shun; Besse, Benjamin; FELIP, ENRIQUETA (Data de publicació: 2024-09-30)

Amivantamab; Biomarkers; Lazertinib

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO

Cappelletti, Vera; Silvestri, Marco; El-Abed, Sarra; Nuciforo, Paolo Giovanni; Di Cosimo, Serena; Ciniselli, Chiara Maura; Pizzamiglio, Sara (Data de publicació: 2023-03-09)

Cáncer de mama HER2 positivo; MicroARN circulante; Tratamiento neoadyuvante

Machine Learning Based Microbiome Signature to Predict Inflammatory Bowel Disease Subtypes

Liñares Blanco, Jose; Fernandez-Lozano, Carlos; Seoane Fernández, Jose Antonio; Lopez-Campos, Guillermo (Data de publicació: 2022-09-09)

Crohn's disease; Microbiome; Ulcerative colitis

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Quintela-Fandino, Miguel; Holgado, Esther; Manso, Luis; Cortés Castan, Javier; Morales, Serafin; Bermejo, Begoña; Colomer, Ramon (Data de publicació: 2021-09-10)

Bevacizumab; Durvalumab; Càncer de mama HER2 negatiu

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

Chen, Joseph; bearz, alessandra; Kim, Dong-Wan; Mamdani, Hirva; Bauman, J. R.; chiari, rita; FELIP, ENRIQUETA (Data de publicació: 2024-02-13)

Lorlatinib; Glycoprotein; Advanced non-small cell lung cancer

Antibody–drug conjugates: smart chemotherapy delivery across tumor histologies

Carmagnani Pestana, Roberto; Corti, Chiara; Modi, Shanu; Tolaney, Sara M; Cortés Castan, Javier; Bardia, Aditya; Tarantino, Paolo (Data de publicació: 2022-07-19)

Antibody-drug conjugates; Enfortumab vedotin; Smart chemotherapy

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer

Seed, George; Beije, Nick; Yuan, Wei; Bertan, Claudia; Goodall, Jane; Lundberg, Arian; Mateo, Joaquin (Data de publicació: 2025-01-17)

DNA repair; Genomics; Prostate cancer

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Bidard, François-Clement; Kaklamani, Virginia; Neven, Patrick; Streich, Guillermo; Montero, Alberto J.; Forget, Frédéric; Cortés Castan, Javier (Data de publicació: 2022-11-04)

Elacestrant; Càncer de mama

Articles científics - VHIO: Enviaments recents

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109) ﻿

Precision Oncology: A Global Perspective on Implementation and Policy Development ﻿

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study ﻿

Barriers to publishing early phase clinical trials: the oncologists’ perspective ﻿

Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein ﻿

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents ﻿

DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas ﻿

Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients ﻿

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients ﻿

Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology ﻿

Mass Spectrometry-Based Proteomics Workflows in Cancer Research: The Relevance of Choosing the Right Steps ﻿

An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry ﻿

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA ﻿

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO ﻿

Machine Learning Based Microbiome Signature to Predict Inflammatory Bowel Disease Subtypes ﻿

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial ﻿

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer ﻿

Antibody–drug conjugates: smart chemotherapy delivery across tumor histologies ﻿

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer ﻿

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial ﻿